Products

Below is a list of the treatments we currently offer via our Innovative Medicines Division. Visit Sandoz and Advanced Accelerator Applications to learn about our generics and radiopharmaceutical products.
Please note: Not all treatments are available in all countries.

Alcon expands leadership position in treating glaucoma through acquisition of Transcend Medical, Inc.
Sandoz strengthens its biosimilars portfolio with acquisition of Pfizer's biosimilar infliximab in EEA
Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim
Novartis Foundation commemorates World Leprosy Day with its continued efforts to go the last mile toward elimination
Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations
Novartis a enregistré, en 2015, une forte croissance des ventes et une hausse de sa marge core (tcc1) et annonce des plans pour accélérer la croissance d'Alcon et rationaliser les opérations du Groupe

Products

Alcon expands leadership position in treating glaucoma through acquisition of Transcend Medical, Inc.

Sandoz strengthens its biosimilars portfolio with acquisition of Pfizer's biosimilar infliximab in EEA

Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim

Novartis Foundation commemorates World Leprosy Day with its continued efforts to go the last mile toward elimination

Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations

Novartis a enregistré, en 2015, une forte croissance des ventes et une hausse de sa marge core (tcc1) et annonce des plans pour accélérer la croissance d'Alcon et rationaliser les opérations du Groupe